Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Major Depressive Disorder Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight's comprehensive report today! @ Major Depressive Disorder Pipeline Outlook
Key Takeaways from the Major Depressive Disorder Pipeline Report
In May 2025, Biohaven Therapeutics Ltd announced a study to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD).
In May 2025, Neurocrine Biosciences conducted a study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
In May 2025, Neumora Therapeutics, Inc. organized a study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
In May 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. announced a phase 2 study parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
In May 2025, Janssen Research & Development LLC announced a study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Medication
Major Depressive Disorder Emerging Drugs Profile
SAGE-217: Sage Therapeutics
SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).
REL-1017: Relmada Therapeutics Inc.
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.
Seltorexant: Minerva Sciences
Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.
SP-624: Sirtsei Pharmaceuticals, Inc.
SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.
SPL026: Small Pharma
SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world's first DMT clinical trial for depression, in collaboration with Imperial College London.
PDC-1421: BioLite Inc.
PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.
The Major Depressive Disorder Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Medication.
Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market
Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Medication. Access DelveInsight's detailed report now! @ New Major Depressive Disorder Drugs
Major Depressive Disorder Companies
GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Subcutaneous
Intravenous
Intramuscular
Major Depressive Disorder Products have been categorized under various Molecule types such as
Bispecific Antibody
Peptides
Small molecule
Gene therapy
Unveil the future of Major Depressive Disorder Medication. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Major Depressive Disorder Market Drivers and Barriers
Scope of the Major Depressive Disorder Pipeline Report
Coverage- Global
Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Major Depressive Disorder Medication and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Major Depressive Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Major Depressive Disorder – DelveInsight's Analytical Perspective
Late Stage Products (Preregistration)
SAGE-217: Sage Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SP-624: Sirtsei Pharmaceuticals, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SPL026: Small Pharma
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
3 hours ago
- National Post
Mia Hughes: Canadian Medical Association wants to force Alberta to ignore science on gender care
Article content The entire field is built upon research out of the Netherlands that has been shown to be methodologically flawed, and the diagnosis of gender dysphoria is shaped by political lobbying intended to reduce stigma and distress. Article content What's more, the Canadian Pediatric Society bases its recommendations on the field's standards of care which are set by the discredited World Professional Association for Transgender Health (WPATH). In a recently withdrawn legal challenge to Alabama's youth gender medicine ban, WPATH was forced to disclose over two million internal emails that revealed the organization blocked independent systematic reviews that showed low-quality evidence, consulted 'social justice lawyers' when drafting its medical guidelines, and, at the Biden administration's request, removed almost all lower age limits from its adolescent chapter to avoid undermining state-level legal battles. Article content Reimer also stated, without irony, that medical decisions should be based on 'the best science.' Yet the best science — specifically the systematic reviews from Sweden, Finland, England, and a team of researchers in Canada — has all concluded the evidence base for paediatric medical transition is of very low certainty. Alberta's Bill 26 reflects that consensus. The CMA's position contradicts it. Article content This isn't the first legal challenge to Alberta's legislation. Late last year, Egale Canada — originally a gay rights charity that expanded into trans advocacy in the early 2000s — teamed up with the Skipping Stone Foundation and five families to contest the law. That move is surprising given early research conducted by leading figures in gender medicine, Psychologist/Sexologist Kenneth Zucker and Psychiatrist Susan Bradley, found that most children with early-onset gender dysphoria would grow up to be gay or lesbian if left untreated, and same-sex attracted teens are overrepresented in the adolescent patients who began flooding gender clinics in the 2010s and among detransitioners. That a gay rights group would back medical interventions that have the potential to sterilize homosexual adolescents is a tragic reversal of purpose. Article content In an interview, Dr. Jake Donaldson, one of three Alberta doctors who filed the challenge alongside the CMA, inadvertently highlighted the questionable rationale for these extreme medical interventions. He believes that puberty blockers and cross-sex hormones help gender-distressed youth blend in better as members of the opposite sex, which makes them 'safer and happier.' But even if that were true — and there is no high-quality evidence to suggest that it is — this approach only offers a superficial, short-term fix that ignores the deeper psychological struggles of these youth. And it can come at such immense long-term cost in the form of sterility, sexual dysfunction, and lifelong medical dependence. Article content 'Medicine is a calling,' explained the CMA president in her statement. 'Doctors pursue it because they are compelled to care for and promote the well-being of patients.' Article content Yet noble intentions are no safeguard against harm. History is littered with medical scandals. At the centre of each one, there were well-intentioned doctors who left a trail of devastation in their quest to help patients. The doctors who prescribed thalidomide didn't do so with the intention of causing major birth defects; the obstetricians who sent expectant mothers for prenatal X-rays didn't deliberately set out to cause childhood leukemia, and Walter Freeman famously believed his prefrontal lobotomies were a humane alternative to the deplorable conditions in insane asylums. Article content At this point, there is little doubt that paediatric gender medicine is destined to take its place in history alongside these medical catastrophes. Therefore, Alberta is not acting unreasonably; it is acting responsibly. By restricting unproven and irreversible treatments for minors, the province has commendably joined a global wave of governments re-asserting evidence and ethical principles in the face of medical groupthink. It is the CMA — not the Alberta government — that must reckon with its conscience. Article content Mia Hughes specializes in researching pediatric gender medicine, psychiatric epidemics, social contagion and the intersection of trans rights and women's rights. She is the author of ' The WPATH Files,' a senior fellow at the Macdonald-Laurier Institute, and director of Genspect Canada. Article content
CTV News
4 hours ago
- CTV News
Vancouver hospital receives $60 million donation to improve care, attract U.S. doctors
Andrew Johnson has the story of a $60-million donation that is expected to enable Vancouver's biggest hospital to create the 'Mayo Clinic of the North.'
Globe and Mail
4 hours ago
- Globe and Mail
To save this baby, doctors had to kill part of her brain
Maryam Fatima was born with a condition called hemimegalencephaly, a rare birth defect in which one side of the brain is abnormally large. She suffered from severe seizures from the moment she was born. They became so bad that they stopped Maryam from feeding, sleeping and breathing. Her life was at risk. That's when a team at the Hospital for Sick Children in Toronto decided to attempt a first-in-Canada procedure to save Maryam's life. Health Science reporter Jennifer Yang interviewed some of the medical professionals who performed the procedure, as well as Maryam's mother, Muzna Nafees. She tells the story of how Maryam's life was saved. Questions? Comments? Ideas? Email us at thedecibel@
